Enterprise Value
40.92M
Cash
19.63M
Avg Qtr Burn
-5.01M
Short % of Float
6.29%
Insider Ownership
17.53%
Institutional Own.
17.76%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Olvi-Vec (Olvimulogene nanivacirepvec) + platinum-doublet + bevacizumab Details Cancer, Platinum-resistant ovarian cancer, Ovarian cancer | Phase 3 Data readout | |
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Small cell lung cancer | Phase 1/2 Data readout |